Cardiac Arrhythmias Associated with Disopyramide

Evlin L. Kinney, Elizabeth H. Field, Michael P. Salmon, Robert Zelis

Research output: Contribution to journalLetter

9 Citations (Scopus)

Abstract

To the Editor: Rare adverse effects of new drugs are often missed in prospective trials.* Disopyramide (Norpace) has been on the United States market since 1977 and began to be used at this medical center in 1978. Shortly thereafter, we suspected that disopyramide might occasionally induce dysrhythmias. We therefore retrospectively reviewed the first 50 disopyramide-treated inpatients at our hospital. In all but one patient (Case 3), disopyramide had been given to suppress premature ventricular contractions. Case 1 was a 67-year-old man with coronary-artery disease and marked left ventricular dilatation, who was admitted with quinidine-induced thrombocytopenia. Disopyramide, 300 mg by mouth. . .

Original languageEnglish (US)
Number of pages1
JournalNew England Journal of Medicine
Volume302
Issue number20
DOIs
StatePublished - May 15 1980

Fingerprint

Disopyramide
Cardiac Arrhythmias
Quinidine
Ventricular Premature Complexes
Thrombocytopenia
Mouth
Inpatients
Coronary Artery Disease
Dilatation
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kinney, Evlin L. ; Field, Elizabeth H. ; Salmon, Michael P. ; Zelis, Robert. / Cardiac Arrhythmias Associated with Disopyramide. In: New England Journal of Medicine. 1980 ; Vol. 302, No. 20.
@article{2130faa40f964e628d3ca2bd8f72a3d5,
title = "Cardiac Arrhythmias Associated with Disopyramide",
abstract = "To the Editor: Rare adverse effects of new drugs are often missed in prospective trials.* Disopyramide (Norpace) has been on the United States market since 1977 and began to be used at this medical center in 1978. Shortly thereafter, we suspected that disopyramide might occasionally induce dysrhythmias. We therefore retrospectively reviewed the first 50 disopyramide-treated inpatients at our hospital. In all but one patient (Case 3), disopyramide had been given to suppress premature ventricular contractions. Case 1 was a 67-year-old man with coronary-artery disease and marked left ventricular dilatation, who was admitted with quinidine-induced thrombocytopenia. Disopyramide, 300 mg by mouth. . .",
author = "Kinney, {Evlin L.} and Field, {Elizabeth H.} and Salmon, {Michael P.} and Robert Zelis",
year = "1980",
month = "5",
day = "15",
doi = "10.1056/NEJM198005153022013",
language = "English (US)",
volume = "302",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "20",

}

Cardiac Arrhythmias Associated with Disopyramide. / Kinney, Evlin L.; Field, Elizabeth H.; Salmon, Michael P.; Zelis, Robert.

In: New England Journal of Medicine, Vol. 302, No. 20, 15.05.1980.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Cardiac Arrhythmias Associated with Disopyramide

AU - Kinney, Evlin L.

AU - Field, Elizabeth H.

AU - Salmon, Michael P.

AU - Zelis, Robert

PY - 1980/5/15

Y1 - 1980/5/15

N2 - To the Editor: Rare adverse effects of new drugs are often missed in prospective trials.* Disopyramide (Norpace) has been on the United States market since 1977 and began to be used at this medical center in 1978. Shortly thereafter, we suspected that disopyramide might occasionally induce dysrhythmias. We therefore retrospectively reviewed the first 50 disopyramide-treated inpatients at our hospital. In all but one patient (Case 3), disopyramide had been given to suppress premature ventricular contractions. Case 1 was a 67-year-old man with coronary-artery disease and marked left ventricular dilatation, who was admitted with quinidine-induced thrombocytopenia. Disopyramide, 300 mg by mouth. . .

AB - To the Editor: Rare adverse effects of new drugs are often missed in prospective trials.* Disopyramide (Norpace) has been on the United States market since 1977 and began to be used at this medical center in 1978. Shortly thereafter, we suspected that disopyramide might occasionally induce dysrhythmias. We therefore retrospectively reviewed the first 50 disopyramide-treated inpatients at our hospital. In all but one patient (Case 3), disopyramide had been given to suppress premature ventricular contractions. Case 1 was a 67-year-old man with coronary-artery disease and marked left ventricular dilatation, who was admitted with quinidine-induced thrombocytopenia. Disopyramide, 300 mg by mouth. . .

UR - http://www.scopus.com/inward/record.url?scp=0018883875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018883875&partnerID=8YFLogxK

U2 - 10.1056/NEJM198005153022013

DO - 10.1056/NEJM198005153022013

M3 - Letter

VL - 302

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 20

ER -